
I-MAB - AMERICAN DEPOSITARY SHARES
Certificado de depósito · US44975P1030 · IMAB · A2PVC6 (XNAS)
2,49 USD
13.06.2025 23:46
Cotizaciones actuales de I-MAB - AMERICAN DEPOSITARY SHARES
Bolsa | Ticker | Moneda | Última operación | Precio | Variación diaria |
---|---|---|---|---|---|
![]() NASDAQ |
IMAB
|
USD
|
13.06.2025 23:46
|
2,49 USD
| 2,64 USD
-5,50 %
|
Rendimiento
Día | Semana | Mes | 3 meses | 6 meses | 1 año | 5 años |
---|---|---|---|---|---|---|
0,00 % | -1,19 % | 179,34 % | 196,08 % | 156,70 % | 35,33 % | -89,63 % |
Perfil de la empresa para I-MAB - AMERICAN DEPOSITARY SHARES Certificado de depósito
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Fondos invertidos
Los siguientes fondos han invertido en: I-MAB - AMERICAN DEPOSITARY SHARES invertido:
Fondo | Vol. en millones 75,32 | Porcentaje (%) 0,18 % |
Fondo | Vol. en millones 2,68 | Porcentaje (%) 0,08 % |
Fondo | Vol. en millones 110,45 | Porcentaje (%) 0,04 % |
Fondo | Vol. en millones 465,11 | Porcentaje (%) 0,04 % |
Fondo | Vol. en millones 7,88 | Porcentaje (%) 0,04 % |
Datos de la empresa
Nombre I-MAB - AMERICAN DEPOSITARY SHARES
Empresa I-Mab
Símbolo IMAB
Sitio web
https://www.i-mabbiopharma.com
Mercado principal
NASDAQ

WKN A2PVC6
ISIN US44975P1030
Tipo de valor Certificado de depósito
Sector Healthcare
Industria Biotechnology
CEO Dr. Xi-Yong Fu M.B.A., Ph.D.
Capitalización de mercado 69 Mio
País China
Moneda USD
Empleados 0,0 T
Dirección New Bund Center, 200124 Shanghai
Fecha de OPV 2020-01-17
Símbolos de cotización
Nombre | Símbolo |
---|---|
Frankfurt | 0VY.F |
NASDAQ | IMAB |
Otras acciones
Los inversores que tienen I-MAB - AMERICAN DEPOSITARY SHARES también tienen las siguientes acciones en su cartera:
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras.
Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.